AR112338A2 - Arilciclohexiléteres de dihidro-tetraazabenzoazuleno - Google Patents
Arilciclohexiléteres de dihidro-tetraazabenzoazulenoInfo
- Publication number
- AR112338A2 AR112338A2 ARP180101972A AR112338A2 AR 112338 A2 AR112338 A2 AR 112338A2 AR P180101972 A ARP180101972 A AR P180101972A AR 112338 A2 AR112338 A2 AR 112338A2
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- unsubstituted
- alkoxy
- substituted
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Reivindicación 1: El compuesto de la fórmula general (1) en la que R¹ es arilo o heteroarilo, sin sustituir o sustituido por uno o más sustituyentes elegidos con independencia entre A; R² es H, alquilo C₁₋₁₂, sin sustituir o sustituido por uno o más OH, halógeno, ciano o alcoxi C₁₋₁₂, -(CH₂)q-Rᵃ, en el que Rᵃ es fenilo o un heteroarilo de 5 ó 6 eslabones, cada uno de ellos está sin sustituir o sustituido por uno o más sustituyentes elegidos con independencia entre A, -(CH₂)ʳNRⁱRⁱⁱ, -C(O)-alquilo C₁₋₁₂, dicho alquilo C₁₋₁₂ está sin sustituir o sustituido por uno o más OH, halógeno, ciano o alcoxi C₁₋₁₂, -C(O)(CH₂)qOC(O)-alquilo C₁₋₁₂, -C(O)(CH₂)qNRⁱRⁱⁱ, -C(O)O-alquilo C₁₋₁₂, dicho alquilo está sin sustituir o sustituido por uno o más OH, halógeno, ciano o alcoxi C₁₋₁₂, -S(O)₂-alquilo C₁₋₁₂, -S(O)₂NRⁱRⁱⁱ, Rⁱ y Rⁱⁱ con independencia entre sí son H, alquilo C₁₋₁₂, o junto con el nitrógeno, al que están unidos, forman un heterocicloalquilo de 3 a 7 eslabones que contiene uno o dos heteroátomos elegidos entre N, O y S, dicho heterocicloalquilo está sin sustituir o sustituido por uno o más sustituyentes elegidos con independencia entre B; q es el número 1, 2, 3 ó 4; r es el número 2, 3 ó 4; A es halógeno, ciano, OH, alquilo C₁₋₇, halo-alquilo C₁₋₇, alcoxi C₁₋₇, halo-alcoxi C₁₋₇ o hidroxi-alquilo C₁₋₇; B es oxo, halógeno, OH, alquilo C₁₋₇ o alcoxi C₁₋₇; R³ es Cl o F; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08170188 | 2008-11-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR112338A2 true AR112338A2 (es) | 2019-10-16 |
Family
ID=41382009
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104565A AR074409A1 (es) | 2008-11-28 | 2009-11-26 | Derivados de arilciclohexileteres de 5,6-dihidro-4h-2,3,5,10-b-tetraaza-benzo[e]azuleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en disfunciones sexuales y trastornos del snc, entre otras patologias. |
| ARP180101972 AR112338A2 (es) | 2008-11-28 | 2018-07-16 | Arilciclohexiléteres de dihidro-tetraazabenzoazuleno |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104565A AR074409A1 (es) | 2008-11-28 | 2009-11-26 | Derivados de arilciclohexileteres de 5,6-dihidro-4h-2,3,5,10-b-tetraaza-benzo[e]azuleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos en disfunciones sexuales y trastornos del snc, entre otras patologias. |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US8227458B2 (es) |
| EP (1) | EP2370441B1 (es) |
| JP (1) | JP5452608B2 (es) |
| KR (1) | KR101359742B1 (es) |
| CN (1) | CN102227428B (es) |
| AR (2) | AR074409A1 (es) |
| AU (1) | AU2009319123B2 (es) |
| BR (1) | BRPI0922303B1 (es) |
| CA (1) | CA2743976C (es) |
| CO (1) | CO6341478A2 (es) |
| CR (1) | CR20110220A (es) |
| CY (1) | CY1115435T1 (es) |
| DK (1) | DK2370441T3 (es) |
| EC (1) | ECSP11011089A (es) |
| ES (1) | ES2431279T3 (es) |
| HK (1) | HK1160642A1 (es) |
| HR (1) | HRP20131067T1 (es) |
| IL (1) | IL212122A (es) |
| MA (1) | MA32781B1 (es) |
| MX (1) | MX2011005596A (es) |
| MY (1) | MY150837A (es) |
| NZ (1) | NZ592076A (es) |
| PE (1) | PE20110582A1 (es) |
| PL (1) | PL2370441T3 (es) |
| PT (1) | PT2370441E (es) |
| RU (1) | RU2507205C2 (es) |
| SG (1) | SG171846A1 (es) |
| SI (1) | SI2370441T1 (es) |
| TW (1) | TWI379833B (es) |
| UA (1) | UA103504C2 (es) |
| WO (1) | WO2010060836A1 (es) |
| ZA (1) | ZA201103419B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013526537A (ja) | 2010-05-13 | 2013-06-24 | アムジエン・インコーポレーテツド | Ｐｄｅ１０阻害剤としてのヘテロアリールオキシカルボシクリル化合物 |
| US8828989B2 (en) * | 2011-09-26 | 2014-09-09 | Hoffmann-La Roche Inc. | Oxy-cyclohexyl-4H,6H-5-oxa-2,3,10b-triaza-benzo[E]azulenes as V1A antagonists |
| CA2847095A1 (en) * | 2011-10-05 | 2013-04-11 | F. Hoffmann-La Roche Ag | Cyclohexyl-4h,6h-5-oxa-2,3,10b-triaza-benzo[e]azulenes as v1a antagonists |
| EA201690179A1 (ru) * | 2013-08-19 | 2016-06-30 | Ф. Хоффманн-Ля Рош Аг | Антагонисты рецептора v1a для лечения расстройств, связанных со сдвигом фазы сна |
| SI3077396T1 (sl) * | 2013-12-05 | 2021-08-31 | F. Hoffmann-La Roche Ag | Sinteza trans-8-kloro-5-metil-1-(4-(piridin-2-iloksi)-cikloheksil)-5,6- dihidro-4H-2,3,5,10b-tetraaza-benzo(e)azulena in njegovih kristalnih oblik |
| WO2017191117A1 (en) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | V1a receptor antagonists for use in the treatment of renal diseases |
| RU2666598C1 (ru) * | 2017-07-14 | 2018-09-11 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Средство для коррекции расстройств аутистического спектра |
| US11033601B2 (en) | 2017-09-14 | 2021-06-15 | The Regents Of The University Of Colorado, A Body Corporate | Selective inhibition of V1b for treating fatty liver |
| EP4082535A1 (en) | 2017-12-08 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical formulation |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| TW201938171A (zh) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物 |
| WO2020139670A1 (en) | 2018-12-27 | 2020-07-02 | Teva Pharmaceuticals International Gmbh | Solid state forms of balovaptan |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521173A (en) | 1995-01-17 | 1996-05-28 | American Home Products Corporation | Tricyclic benzazepine vasopressin antagonists |
| ME00129B (me) | 1999-01-19 | 2010-10-10 | Ortho Mcneil Janssen Pharmaceuticals Inc | Triciklicnj benzodiazepini kao antagonisti receptora vazopresina |
| TWI239333B (en) * | 2000-11-16 | 2005-09-11 | Hoffmann La Roche | Benzodiazepine derivatives as GABA A receptor modulators |
| US7022699B2 (en) | 2001-04-12 | 2006-04-04 | Wyeth | Cyclohexenyl phenyl diazepines vasopressin and oxytocin receptor modulators |
| GB0303852D0 (en) | 2003-02-19 | 2003-03-26 | Pfizer Ltd | Triazole compounds useful in therapy |
| GB0400700D0 (en) * | 2004-01-13 | 2004-02-18 | Pfizer Ltd | Compounds useful in therapy |
| CN1950374A (zh) | 2004-05-25 | 2007-04-18 | 辉瑞产品公司 | 四氮杂苯并[e]甘菊环衍生物及其类似物 |
| KR100840852B1 (ko) | 2004-05-25 | 2008-06-23 | 화이자 프로덕츠 인크. | 테트라아자벤조[ｅ]아줄렌 유도체 및 이의 유사체 |
| EP1632494A1 (en) | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonists |
| JP2008510789A (ja) * | 2004-08-25 | 2008-04-10 | ファイザー・インク | トリアゾロベンゾジアゼピン及びバゾプレシンアンタゴニストとしてのそれらの使用 |
| EP1877399A1 (en) | 2005-04-26 | 2008-01-16 | Pfizer Limited | Triazole derivatives as vasopressin antagonists |
| WO2006123242A1 (en) | 2005-05-18 | 2006-11-23 | Pfizer Limited | 1, 2, 4 -triazole derivatives as vasopressin antagonists |
| MX2009007411A (es) | 2007-01-12 | 2009-07-17 | Hoffmann La Roche | Derivados de espiropiperidina-glicinamida. |
| ES2466022T3 (es) * | 2008-04-09 | 2014-06-09 | Kuraray Co., Ltd. | Producto estratificado de barrera para gas y método de producción del mismo |
| EP2356123B1 (en) | 2008-11-13 | 2012-10-03 | F.Hoffmann-La Roche Ag | Spiro-5,6-dihydro-4h-2,3,5,10b-tetraaza-benzo[e]azulenes |
| WO2010057795A1 (en) * | 2008-11-18 | 2010-05-27 | F. Hoffmann-La Roche Ag | Alkylcyclohexylethers of dihydrotetraazabenzoazulenes |
| US8420633B2 (en) | 2010-03-31 | 2013-04-16 | Hoffmann-La Roche Inc. | Aryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8461151B2 (en) | 2010-04-13 | 2013-06-11 | Hoffmann-La Roche Inc. | Aryl-/heteroaryl-cyclohexenyl-tetraazabenzo[e]azulenes |
| US8492376B2 (en) | 2010-04-21 | 2013-07-23 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8481528B2 (en) | 2010-04-26 | 2013-07-09 | Hoffmann-La Roche Inc. | Heterobiaryl-cyclohexyl-tetraazabenzo[e]azulenes |
| US8513238B2 (en) | 2010-05-10 | 2013-08-20 | Hoffmann-La Roche Inc. | Heteroaryl-cyclohexyl-tetraazabenzo[E]azulenes |
-
2009
- 2009-11-18 BR BRPI0922303-7A patent/BRPI0922303B1/pt active IP Right Grant
- 2009-11-18 EP EP09752380.7A patent/EP2370441B1/en active Active
- 2009-11-18 SI SI200930769T patent/SI2370441T1/sl unknown
- 2009-11-18 MY MYPI20112399 patent/MY150837A/en unknown
- 2009-11-18 RU RU2011123703/04A patent/RU2507205C2/ru active
- 2009-11-18 SG SG2011038692A patent/SG171846A1/en unknown
- 2009-11-18 MX MX2011005596A patent/MX2011005596A/es active IP Right Grant
- 2009-11-18 KR KR1020117012049A patent/KR101359742B1/ko active IP Right Grant
- 2009-11-18 UA UAA201107950A patent/UA103504C2/ru unknown
- 2009-11-18 CA CA2743976A patent/CA2743976C/en active Active
- 2009-11-18 PE PE2011001019A patent/PE20110582A1/es active IP Right Grant
- 2009-11-18 ES ES09752380T patent/ES2431279T3/es active Active
- 2009-11-18 PL PL09752380T patent/PL2370441T3/pl unknown
- 2009-11-18 JP JP2011537933A patent/JP5452608B2/ja active Active
- 2009-11-18 WO PCT/EP2009/065354 patent/WO2010060836A1/en active Application Filing
- 2009-11-18 AU AU2009319123A patent/AU2009319123B2/en active Active
- 2009-11-18 NZ NZ592076A patent/NZ592076A/en unknown
- 2009-11-18 CN CN200980147825.3A patent/CN102227428B/zh active Active
- 2009-11-18 PT PT97523807T patent/PT2370441E/pt unknown
- 2009-11-18 DK DK09752380.7T patent/DK2370441T3/da active
- 2009-11-19 US US12/621,547 patent/US8227458B2/en active Active
- 2009-11-25 TW TW098140192A patent/TWI379833B/zh active
- 2009-11-26 AR ARP090104565A patent/AR074409A1/es active IP Right Grant
-
2011
- 2011-03-31 CO CO11039945A patent/CO6341478A2/es active IP Right Grant
- 2011-04-04 IL IL212122A patent/IL212122A/en active IP Right Grant
- 2011-04-28 CR CR20110220A patent/CR20110220A/es unknown
- 2011-05-10 ZA ZA2011/03419A patent/ZA201103419B/en unknown
- 2011-05-10 MA MA33827A patent/MA32781B1/fr unknown
- 2011-05-26 EC EC2011011089A patent/ECSP11011089A/es unknown
-
2012
- 2012-02-02 HK HK12100967.5A patent/HK1160642A1/xx unknown
- 2012-05-15 US US13/471,491 patent/US8461152B2/en active Active
-
2013
- 2013-10-24 CY CY20131100939T patent/CY1115435T1/el unknown
- 2013-11-08 HR HRP20131067AT patent/HRP20131067T1/hr unknown
-
2018
- 2018-07-16 AR ARP180101972 patent/AR112338A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR112338A2 (es) | Arilciclohexiléteres de dihidro-tetraazabenzoazuleno | |
| AR109958A1 (es) | Lactamas bicíclicas de piridona y sus métodos de uso | |
| AR115296A1 (es) | Heterocíclicos inhibidores de mat2a y métodos de uso para el tratamiento del cáncer | |
| AR108710A1 (es) | Compuestos modulares de fxr (nr1h4) | |
| AR091962A1 (es) | Compuesto antidiabeticos triciclicos | |
| AR110405A1 (es) | Compuestos | |
| AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
| AR090868A1 (es) | Composiciones plaguicidas y procesos relacionados con ellas | |
| AR093515A1 (es) | Triazolopirazinas | |
| AR082886A1 (es) | Compuestos y composiciones farmaceuticas que los contienen | |
| AR092742A1 (es) | Piridinonas antifibroticas | |
| AR078609A1 (es) | 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central,tales como depresion y canceres de ovario y renales, entre otros. | |
| AR100645A1 (es) | Derivados de pirazolo-pirimidina | |
| AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR090328A1 (es) | Pirrolidina-2-carboxamidas sustituidas | |
| AR090076A1 (es) | Metodos para producir compuestos sulfilimina | |
| AR097866A1 (es) | Derivados de 4-azaindol | |
| AR099646A1 (es) | Fotoestabilizantes de aminas impedidas | |
| AR091271A1 (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa | |
| AR100712A1 (es) | Compuestos de pirazol como bloqueadores de los canales de calcio tipo t | |
| AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
| AR110282A1 (es) | Compuestos de amida bicíclica y uso de éstos en el tratamiento de enfermedades mediadas por rip1 | |
| AR087274A1 (es) | Derivados de amidas heterociclicas como antagonistas de receptores p2x7 | |
| AR103742A1 (es) | Derivados de trifluorometilpropanamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |